

## Supplementary data: References Supplementary Table 1

### Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material

Elisabeth M.P. Steeghs<sup>1,\*</sup>, Leonie I. Kroeze<sup>1,\*</sup>, Bastiaan B.J. Tops<sup>1,2</sup>, Leon C. van Kempen<sup>3</sup>, Arja ter Elst<sup>3</sup>, Annemiek W.M. Kastner-van Raaij<sup>1</sup>, Sandra J.B. Hendriks-Cornelissen<sup>1</sup>, Mandy J.W. Hermsen<sup>1</sup>, Erik A.M. Jansen<sup>5</sup>, Petra M. Nederlof<sup>4</sup>, Ed Schuurin<sup>3</sup>, Marjolijn J.L. Ligtenberg<sup>1,5,\*</sup>, Astrid Eijkelenboom<sup>1,\*</sup>

*\* authors contributed equally*

<sup>1</sup> Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands

<sup>2</sup> Department of Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

<sup>3</sup> Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>4</sup> Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

<sup>5</sup> Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands

Corresponding author:

Astrid Eijkelenboom, PhD

Radboud University Medical Center

PO Box 9101, 6500 HB, Nijmegen, the Netherlands

E-mail: Astrid.Eijkelenboom@radboudumc.nl

Phone: 0031-243655374, Fax: 0031-243668750

- 1 1. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses  
2 TY, Savage S *et al*: **A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.**  
3 *Nature* 2007, **448**(7152):439-444.
- 4 2. Yi KH, Lauring J: **Recurrent AKT mutations in human cancers: functional consequences and effects on**  
5 **drug sensitivity.** *Oncotarget* 2016, **7**(4):4241-4251.
- 6 3. Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H *et al*:  
7 **Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.**  
8 *Proc Natl Acad Sci U S A* 2012, **109**(47):19368-19373.
- 9 4. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills  
10 GB: **A novel AKT3 mutation in melanoma tumours and cell lines.** *Br J Cancer* 2008, **99**(8):1265-1268.
- 11 5. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzemberger BC, Khotskaya YB, Sanchez NS, Zeng J,  
12 Shufean MA, Shaw KR *et al*: **ALK: a tyrosine kinase target for cancer therapy.** *Cold Spring Harb Mol*  
13 *Case Stud* 2017, **3**(1):a001115.
- 14 6. Drizou M, Kotteas EA, Syrigos N: **Treating patients with ALK-rearranged non-small-cell lung cancer:**  
15 **mechanisms of resistance and strategies to overcome it.** *Clin Transl Oncol* 2017, **19**(6):658-666.
- 16 7. Salido M, Pijuan L, Martinez-Aviles L, Galvan AB, Canadas I, Rovira A, Zanui M, Martinez A, Longaron R,  
17 Sole F *et al*: **Increased ALK gene copy number and amplification are frequent in non-small cell lung**  
18 **cancer.** *J Thorac Oncol* 2011, **6**(1):21-27.
- 19 8. Katayama R: **Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma**  
20 **kinase (ALK)-rearranged lung cancer.** *Pharmacol Ther* 2017, **177**:1-8.
- 21 9. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, Schiller J, Villalona-Calero MA, Meyerson  
22 M, Carbone DP: **Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.** *J Clin*  
23 *Invest* 2014, **124**(4):1582-1586.
- 24 10. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB *et al*:  
25 **Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-**  
26 **RAF inhibitor resistance.** *Nat Commun* 2012, **3**:724.
- 27 11. Tsao H, Chin L, Garraway LA, Fisher DE: **Melanoma: from mutations to medicine.** *Genes Dev* 2012,  
28 **26**(11):1131-1155.

- 29 12. Sasaki H, Maekawa M, Tatematsu T, Okuda K, Moriyama S, Yano M, Fujii Y: **Increased BRAF copy**  
30 **number in lung adenocarcinoma.** *Oncol Lett* 2015, **9**(2):709-712.
- 31 13. Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood  
32 JM, Kluger HM *et al*: **Copy Number Changes Are Associated with Response to Treatment with**  
33 **Carboplatin, Paclitaxel, and Sorafenib in Melanoma.** *Clin Cancer Res* 2016, **22**(2):374-382.
- 34 14. Barras D: **BRAF Mutation in Colorectal Cancer: An Update.** *Biomark Cancer* 2015, **7**(Suppl 1):9-12.
- 35 15. Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M,  
36 Hammerman PS: **Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2**  
37 **gatekeeper mutation and NF1 loss.** *Mol Cancer Ther* 2014, **13**(2):475-482.
- 38 16. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J *et al*:  
39 **Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.**  
40 *Cancer Discov* 2011, **1**(1):78-89.
- 41 17. Lee MS, Jung EA, An SB, Kim YJ, Oh DY, Song JY, Um SW, Han J, Choi YL: **Prevalence of Mutations in**  
42 **Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in**  
43 **Korean Patients.** *Cancer Res Treat* 2017, **49**(4):1065-1076.
- 44 18. Miao L, Wang Y, Zhu S, Shi M, Li Y, Ding J, Yang J, Ye Q, Cai H, Zhang D *et al*: **Identification of novel**  
45 **driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of**  
46 **Chinese patients.** *BMC Cancer* 2014, **14**:369.
- 47 19. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim  
48 C *et al*: **The genomic landscape of response to EGFR blockade in colorectal cancer.** *Nature* 2015,  
49 **526**(7572):263-267.
- 50 20. Gan HK, Cvriljevic AN, Johns TG: **The epidermal growth factor receptor variant III (EGFRvIII): where**  
51 **wild things are altered.** *FEBS J* 2013, **280**(21):5350-5370.
- 52 21. Metzger B, Chambeau L, Begon DY, Faber C, Kayser J, Berchem G, Pauly M, Boniver J, Delvenne P,  
53 Dicato M *et al*: **The human epidermal growth factor receptor (EGFR) gene in European patients with**  
54 **advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.** *BMC Med*  
55 *Genet* 2011, **12**:144.

- 56 22. Peciak J, Stec WJ, Treda C, Ksiazkiewicz M, Janik K, Popeda M, Smolarz M, Rosiak K, Hulas-Bigoszewska  
57 K, Och W *et al*: **Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal**  
58 **Cancers Compared to Glioblastoma.** *J Cancer* 2017, **8**(1):146-151.
- 59 23. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y: **EGFRvIII mutation in lung cancer correlates**  
60 **with increased EGFR copy number.** *Oncol Rep* 2007, **17**(2):319-323.
- 61 24. Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J,  
62 Trusolino L *et al*: **HER2 activating mutations are targets for colorectal cancer treatment.** *Cancer*  
63 *Discov* 2015, **5**(8):832-841.
- 64 25. Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA,  
65 Yelensky R *et al*: **Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across**  
66 **tumors from diverse anatomic sites of origin.** *Oncologist* 2015, **20**(1):7-12.
- 67 26. Herter-Sprie GS, Greulich H, Wong KK: **Activating Mutations in ERBB2 and Their Impact on**  
68 **Diagnostics and Treatment.** *Front Oncol* 2013, **3**:86.
- 69 27. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, Lee HS: **HER2 status in colorectal cancer: its**  
70 **clinical significance and the relationship between HER2 gene amplification and expression.** *PLoS One*  
71 2014, **9**(5):e98528.
- 72 28. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler  
73 PJ, Melnick MA *et al*: **HER2 amplification: a potential mechanism of acquired resistance to EGFR**  
74 **inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation.** *Cancer*  
75 *Discov* 2012, **2**(10):922-933.
- 76 29. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R: **The FGFR Landscape in Cancer: Analysis**  
77 **of 4,853 Tumors by Next-Generation Sequencing.** *Clin Cancer Res* 2016, **22**(1):259-267.
- 78 30. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E,  
79 Nakamura Y *et al*: **FGFR gene alterations in lung squamous cell carcinoma are potential targets for**  
80 **the multikinase inhibitor nintedanib.** *Cancer Sci* 2016, **107**(11):1667-1676.
- 81 31. Katoh M, Nakagama H: **FGF receptors: cancer biology and therapeutics.** *Med Res Rev* 2014, **34**(2):280-  
82 300.
- 83 32. Pfarr N, Penzel R, Klauschen F, Heim D, Brandt R, Kazdal D, Jesinghaus M, Herpel E, Schirmacher P,  
84 Warth A *et al*: **Copy number changes of clinically actionable genes in melanoma, non-small cell lung**

- 85 **cancer and colorectal cancer-A survey across 822 routine diagnostic cases.** *Genes Chromosomes*  
86 *Cancer* 2016, **55**(11):821-833.
- 87 33. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS: **The**  
88 **emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.** *Nat Rev*  
89 *Cancer* 2013, **13**(6):412-424.
- 90 34. van Dijk MC, Bernsen MR, Ruiter DJ: **Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the**  
91 **differential diagnosis of Spitz nevus and spitzoid melanoma.** *Am J Surg Pathol* 2005, **29**(9):1145-1151.
- 92 35. van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, Blokk WA: **HRAS-mutated**  
93 **Spitz tumors: A subtype of Spitz tumors with distinct features.** *Am J Surg Pathol* 2010, **34**(10):1436-  
94 1441.
- 95 36. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N: **Mutant IDH1 confers an in vivo growth in**  
96 **a melanoma cell line with BRAF mutation.** *Am J Pathol* 2011, **178**(3):1395-1402.
- 97 37. Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y,  
98 Yan H: **IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with**  
99 **metastases to the brain.** *Biochem Biophys Res Commun* 2010, **398**(3):585-587.
- 100 38. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T,  
101 Brennan KW *et al*: **Identification of new ALK and RET gene fusions from colorectal and lung cancer**  
102 **biopsies.** *Nat Med* 2012, **18**(3):382-384.
- 103 39. Dumaz N, Andre J, Sadoux A, Laugier F, Podgorniak MP, Mourah S, Lebbe C: **Driver KIT mutations in**  
104 **melanoma cluster in four hotspots.** *Melanoma Res* 2015, **25**(1):88-90.
- 105 40. Todd JR, Becker TM, Kefford RF, Rizos H: **Secondary c-Kit mutations confer acquired resistance to RTK**  
106 **inhibitors in c-Kit mutant melanoma cells.** *Pigment Cell Melanoma Res* 2013, **26**(4):518-526.
- 107 41. Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S: **Targeted therapy in GIST: in silico modeling for**  
108 **prediction of resistance.** *Nat Rev Clin Oncol* 2011, **8**(3):161-170.
- 109 42. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, 3rd,  
110 Azar S *et al*: **KIT gene mutations and copy number in melanoma subtypes.** *Clin Cancer Res* 2008,  
111 **14**(21):6821-6828.
- 112 43. Karachaliou N, Mayo C, Costa C, Magri I, Gimenez-Capitan A, Molina-Vila MA, Rosell R: **KRAS**  
113 **mutations in lung cancer.** *Clin Lung Cancer* 2013, **14**(3):205-214.

- 114 44. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,  
115 Siravegna G *et al*: **Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in**  
116 **colorectal cancer**. *Nature* 2012, **486**(7404):532-536.
- 117 45. Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R, Reischl M, Mikut R, Rubin MA, Fend  
118 F *et al*: **Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung**  
119 **carcinoma**. *Lung Cancer* 2011, **74**(1):118-123.
- 120 46. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs  
121 B, Ercolani C *et al*: **KRAS gene amplification in colorectal cancer and impact on response to EGFR-**  
122 **targeted therapy**. *Int J Cancer* 2013, **133**(5):1259-1265.
- 123 47. Arcila ME, Drlon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M: **MAP2K1**  
124 **(MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking**. *Clin*  
125 *Cancer Res* 2015, **21**(8):1935-1943.
- 126 48. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D *et al*:  
127 **Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor**  
128 **signaling pathway genes in lung adenocarcinoma**. *Cancer Res* 2008, **68**(14):5524-5528.
- 129 49. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete  
130 V *et al*: **Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in**  
131 **melanoma**. *Nat Genet* 2011, **44**(2):133-139.
- 132 50. Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zyllicz M, Jakobkiewicz-Banecka J,  
133 Kobierska-Gulida G, Szymanowska A, Skokowski J *et al*: **MDM2 gene amplification: a new**  
134 **independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)**. *Lung Cancer* 2004,  
135 **43**(3):285-295.
- 136 51. Hav M, Libbrecht L, Ferdinande L, Pattyn P, Laurent S, Peeters M, Praet M, Pauwels P: **MDM2 gene**  
137 **amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic**  
138 **option?** *Virchows Arch* 2011, **458**(2):197-203.
- 139 52. Tornillo L, Duchini G, Carafa V, Lugli A, Dirnhofer S, Di Vizio D, Boscaino A, Russo R, Tapia C, Schneider-  
140 Stock R *et al*: **Patterns of gene amplification in gastrointestinal stromal tumors (GIST)**. *Lab Invest*  
141 2005, **85**(7):921-931.

- 142 53. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Janne  
143 PA, Verma S *et al*: **MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With**  
144 **Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.** *J Clin*  
145 *Oncol* 2016, **34**(7):721-730.
- 146 54. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bifulca JA, Lee C, Jentz D  
147 *et al*: **Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and**  
148 **confers clinical sensitivity to MET inhibitors.** *Cancer Discov* 2015, **5**(8):850-859.
- 149 55. Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde  
150 P, Leuenberger K *et al*: **Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14**  
151 **Skipping Alterations.** *J Thorac Oncol* 2016, **11**(9):1493-1502.
- 152 56. Lee J, Ou SH, Lee JM, Kim HC, Hong M, Kim SY, Jang J, Ahn S, Kang SY, Lee S *et al*: **Gastrointestinal**  
153 **malignancies harbor actionable MET exon 14 deletions.** *Oncotarget* 2015, **6**(29):28211-28222.
- 154 57. Zenali M, deKay J, Liu Z, Hamilton S, Zuo Z, Lu X, Bakkar R, Mills G, Broaddus R: **Retrospective Review**  
155 **of MET Gene Mutations.** *Oncoscience* 2015, **2**(5):533-541.
- 156 58. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM: **A**  
157 **diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin**  
158 **sensitivity.** *Cancer Discov* 2014, **4**(5):554-563.
- 159 59. Kong Y, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X *et al*: **Analysis of mTOR Gene**  
160 **Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway**  
161 **Inhibitors.** *Clin Cancer Res* 2016, **22**(4):1018-1027.
- 162 60. Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W,  
163 Berger M, de Stanchina E *et al*: **Overcoming mTOR resistance mutations with a new-generation**  
164 **mTOR inhibitor.** *Nature* 2016, **534**(7606):272-276.
- 165 61. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL,  
166 Berry L *et al*: **Characteristics of lung cancers harboring NRAS mutations.** *Clin Cancer Res* 2013,  
167 **19**(9):2584-2591.
- 168 62. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C,  
169 Marmorino F, Sensi E *et al*: **Role of NRAS mutations as prognostic and predictive markers in**  
170 **metastatic colorectal cancer.** *Int J Cancer* 2015, **136**(1):83-90.

- 171 63. Boespflug A, Caramel J, Dalle S, Thomas L: **Treatment of NRAS-mutated advanced or metastatic**  
172 **melanoma: rationale, current trials and evidence to date.** *Ther Adv Med Oncol* 2017, **9(7)**:481-492.
- 173 64. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J,  
174 Heinrich MC: **PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in**  
175 **vitro sensitivity to imatinib.** *J Clin Oncol* 2005, **23(23)**:5357-5364.
- 176 65. Dai J, Kong Y, Si L, Chi Z, Cui C, Sheng X, Mao L, Li S, Lian B, Yang R *et al*: **Large-scale analysis of**  
177 **PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors**  
178 **imatinib and crenolanib.** *Clin Cancer Res* 2013, **19(24)**:6935-6942.
- 179 66. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H,  
180 Roesel J *et al*: **Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and**  
181 **activity of the PKC412 inhibitor against imatinib-resistant mutants.** *Gastroenterology* 2005,  
182 **128(2)**:270-279.
- 183 67. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M: **Cancer-specific mutations in phosphatidylinositol 3-**  
184 **kinase.** *Trends Biochem Sci* 2007, **32(7)**:342-349.
- 185 68. Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, Yu Y, Li H, Cai D, Sun Y *et al*: **PIK3CA mutations frequently**  
186 **coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in**  
187 **EGFR/KRAS wildtype subgroup.** *PLoS One* 2014, **9(2)**:e88291.
- 188 69. Gymnopoulos M, Elsliger MA, Vogt PK: **Rare cancer-specific mutations in PIK3CA show gain of**  
189 **function.** *Proc Natl Acad Sci U S A* 2007, **104(13)**:5569-5574.
- 190 70. Manca A, Lissia A, Capone M, Ascierto PA, Botti G, Caraco C, Stanganelli I, Colombino M, Sini M, Cossu  
191 A *et al*: **Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of**  
192 **melanomas.** *J Transl Med* 2015, **13**:37.
- 193 71. Ahn SM, Ansari AA, Kim J, Kim D, Chun SM, Kim J, Kim TW, Park I, Yu CS, Jang SJ: **The somatic POLE**  
194 **P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation,**  
195 **representing a potential genomic biomarker for immunotherapy.** *Oncotarget* 2016, **7(42)**:68638-  
196 68649.
- 197 72. Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A,  
198 Morreau H *et al*: **Somatic POLE proofreading domain mutation, immune response, and prognosis in**



- 199            **colorectal cancer: a retrospective, pooled biomarker study.** *Lancet Gastroenterol Hepatol* 2016,  
200            **1(3):207-216.**
- 201    73.    Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, Cha SI, Yoon GS, Kim CH, Jung TH *et al*: **PTEN**  
202            **mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung**  
203            **cancers.** *Lung Cancer* 2010, **69(3):279-283.**
- 204    74.    Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, Eshleman JR: **Mutational profiling of colorectal**  
205            **cancers with microsatellite instability.** *Oncotarget* 2015, **6(39):42334-42344.**
- 206    75.    Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B, Segelov E: **PTEN mutations**  
207            **are common in sporadic microsatellite stable colorectal cancer.** *Oncogene* 2004, **23(2):617-628.**
- 208    76.    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon  
209            *J et al*: **Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for**  
210            **ROS1- and ALK-Rearranged Lung Cancers.** *Clin Cancer Res* 2016, **22(24):5983-5991.**
- 211    77.    Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS: **Molecular Changes Associated with**  
212            **Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.** *Clin Cancer Res*  
213            2015, **21(10):2379-2387.**
- 214    78.    Olivier M, Hollstein M, Hainaut P: **TP53 mutations in human cancers: origins, consequences, and**  
215            **clinical use.** *Cold Spring Harb Perspect Biol* 2010, **2(1):a001008.**
- 216    79.    Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R:  
217            **Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats**  
218            **and pentaplex PCR.** *Gastroenterology* 2002, **123(6):1804-1811.**